DE3628190A1 - Pharmazeutische zusammensetzung zur behandlung von parathyreoid-hormon induzierter knochenresorption - Google Patents
Pharmazeutische zusammensetzung zur behandlung von parathyreoid-hormon induzierter knochenresorptionInfo
- Publication number
- DE3628190A1 DE3628190A1 DE19863628190 DE3628190A DE3628190A1 DE 3628190 A1 DE3628190 A1 DE 3628190A1 DE 19863628190 DE19863628190 DE 19863628190 DE 3628190 A DE3628190 A DE 3628190A DE 3628190 A1 DE3628190 A1 DE 3628190A1
- Authority
- DE
- Germany
- Prior art keywords
- composition according
- peroxydiphosphate
- bone resorption
- pth
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000006386 Bone Resorption Diseases 0.000 title claims description 18
- 230000024279 bone resorption Effects 0.000 title claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 229940088597 hormone Drugs 0.000 title 1
- 239000005556 hormone Substances 0.000 title 1
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 6
- 230000037396 body weight Effects 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 231100000252 nontoxic Toxicity 0.000 claims description 6
- 230000003000 nontoxic effect Effects 0.000 claims description 6
- 239000000199 parathyroid hormone Substances 0.000 claims description 6
- 125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 claims description 5
- 125000001417 5'-guanylyl group Chemical group C=12N=C(N([H])[H])N([H])C(=O)C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 claims description 5
- 238000000576 coating method Methods 0.000 claims description 5
- 229960001319 parathyroid hormone Drugs 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 230000000968 intestinal effect Effects 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 210000002784 stomach Anatomy 0.000 claims description 4
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 238000007910 systemic administration Methods 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 230000001698 pyrogenic effect Effects 0.000 claims 1
- 229910052718 tin Inorganic materials 0.000 claims 1
- 239000011135 tin Substances 0.000 claims 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 31
- 210000000988 bone and bone Anatomy 0.000 description 11
- 239000011575 calcium Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 9
- -1 alkali metal salts Chemical class 0.000 description 9
- 229910052791 calcium Inorganic materials 0.000 description 9
- 230000028327 secretion Effects 0.000 description 7
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 238000005115 demineralization Methods 0.000 description 6
- 230000002328 demineralizing effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 208000013038 Hypocalcemia Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000000705 hypocalcaemia Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 210000004872 soft tissue Anatomy 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- PEKPGBKEIWFPAS-UHFFFAOYSA-J tetrapotassium;[oxido(oxidooxy)phosphoryl] phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]OP([O-])(=O)OP([O-])([O-])=O PEKPGBKEIWFPAS-UHFFFAOYSA-J 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000012454 limulus amebocyte lysate test Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000011034 membrane dialysis Methods 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000030991 negative regulation of bone resorption Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 150000002895 organic esters Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- NUGJFLYPGQISPX-UHFFFAOYSA-N peroxydiphosphoric acid Chemical class OP(O)(=O)OOP(O)(O)=O NUGJFLYPGQISPX-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 159000000008 strontium salts Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76839485A | 1985-08-22 | 1985-08-22 | |
| US85191486A | 1986-04-14 | 1986-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3628190A1 true DE3628190A1 (de) | 1987-02-26 |
Family
ID=27118048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19863628190 Withdrawn DE3628190A1 (de) | 1985-08-22 | 1986-08-20 | Pharmazeutische zusammensetzung zur behandlung von parathyreoid-hormon induzierter knochenresorption |
Country Status (10)
| Country | Link |
|---|---|
| BE (1) | BE905318A (enrdf_load_html_response) |
| CH (1) | CH669731A5 (enrdf_load_html_response) |
| DE (1) | DE3628190A1 (enrdf_load_html_response) |
| DK (1) | DK164443C (enrdf_load_html_response) |
| FR (1) | FR2586350B1 (enrdf_load_html_response) |
| GB (1) | GB2179255B (enrdf_load_html_response) |
| HK (1) | HK1293A (enrdf_load_html_response) |
| IT (1) | IT1196586B (enrdf_load_html_response) |
| NL (1) | NL8602139A (enrdf_load_html_response) |
| SE (1) | SE468625B (enrdf_load_html_response) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007020155A1 (de) | 2007-04-26 | 2008-10-30 | Hein Lehmann Trenn- und Fördertechnik GmbH | Befestigungssystem für flexible Siebmatten |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4041149A (en) * | 1976-01-12 | 1977-08-09 | Colgate-Palmolive Company | Composition and method of controlling and preventing mouth odor |
| DE3523263A1 (de) * | 1984-06-27 | 1986-01-09 | Colgate-Palmolive Co., New York, N.Y. | Arzneimittel |
| DE3610179A1 (de) * | 1985-04-16 | 1986-10-23 | Colgate Palmolive Co | Orale zubereitung, insbesondere zur bekaempfung von mundgeruch |
| DE3627759A1 (de) * | 1985-08-22 | 1987-03-19 | Colgate Palmolive Co | Pharmazeutische zusammensetzung zum inaktivieren bakterieller endotoxine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4430325A (en) * | 1981-12-23 | 1984-02-07 | Colgate-Palmolive Company | Topical treatment of skin lesions |
-
1986
- 1986-08-18 FR FR868611811A patent/FR2586350B1/fr not_active Expired - Lifetime
- 1986-08-19 SE SE8603485A patent/SE468625B/sv not_active IP Right Cessation
- 1986-08-19 IT IT48388/86A patent/IT1196586B/it active
- 1986-08-20 DE DE19863628190 patent/DE3628190A1/de not_active Withdrawn
- 1986-08-22 GB GB8620481A patent/GB2179255B/en not_active Expired
- 1986-08-22 BE BE0/217072A patent/BE905318A/fr not_active IP Right Cessation
- 1986-08-22 NL NL8602139A patent/NL8602139A/nl not_active Application Discontinuation
- 1986-08-22 CH CH3378/86A patent/CH669731A5/de not_active IP Right Cessation
- 1986-08-22 DK DK401986A patent/DK164443C/da not_active IP Right Cessation
-
1993
- 1993-01-14 HK HK12/93A patent/HK1293A/xx unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4041149A (en) * | 1976-01-12 | 1977-08-09 | Colgate-Palmolive Company | Composition and method of controlling and preventing mouth odor |
| DE3523263A1 (de) * | 1984-06-27 | 1986-01-09 | Colgate-Palmolive Co., New York, N.Y. | Arzneimittel |
| DE3610179A1 (de) * | 1985-04-16 | 1986-10-23 | Colgate Palmolive Co | Orale zubereitung, insbesondere zur bekaempfung von mundgeruch |
| DE3627759A1 (de) * | 1985-08-22 | 1987-03-19 | Colgate Palmolive Co | Pharmazeutische zusammensetzung zum inaktivieren bakterieller endotoxine |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007020155A1 (de) | 2007-04-26 | 2008-10-30 | Hein Lehmann Trenn- und Fördertechnik GmbH | Befestigungssystem für flexible Siebmatten |
Also Published As
| Publication number | Publication date |
|---|---|
| DK401986A (da) | 1987-02-23 |
| FR2586350A1 (fr) | 1987-02-27 |
| BE905318A (fr) | 1987-02-23 |
| IT1196586B (it) | 1988-11-16 |
| HK1293A (en) | 1993-01-21 |
| SE468625B (sv) | 1993-02-22 |
| FR2586350B1 (fr) | 1992-05-15 |
| GB2179255A (en) | 1987-03-04 |
| SE8603485D0 (sv) | 1986-08-19 |
| GB8620481D0 (en) | 1986-10-01 |
| SE8603485L (sv) | 1987-02-23 |
| NL8602139A (nl) | 1987-03-16 |
| IT8648388A0 (it) | 1986-08-19 |
| DK401986D0 (da) | 1986-08-22 |
| DK164443B (da) | 1992-06-29 |
| DK164443C (da) | 1992-11-16 |
| GB2179255B (en) | 1989-10-11 |
| CH669731A5 (enrdf_load_html_response) | 1989-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1059920B1 (de) | Verwendung von alkylhydrogenfumaraten zur behandlung von psoriasis, psoriatischer arthritis, neurodermitis und enteritis regionalis crohn | |
| DE4215677B4 (de) | Pharmazeutisches Mittel | |
| DE69822665T2 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| DE3382641T2 (de) | Arzneimittel fuer die therapeutische behandlung von alopezie. | |
| DE3907649C2 (de) | Arzneimittel, geeignet bei der Bekämpfung von Viren und zur Immunstimulierung | |
| DE2822789C2 (de) | N-Acetyl-DL-methionin-(p-acetylaminophenyl)-ester, Verfahren zu seiner Herstellung und seine Verwendung | |
| DE3430799A1 (de) | Verfahren zur behandlung von osteoporose | |
| EP0236951A2 (de) | Verwendung von Diphenylhydantoin und seinen Derivaten zur Herstellung eines pharmazeutischen Mittels zur Behandlung von Immunerkrankungen | |
| EP0214620A2 (de) | Transdermale Applikationsform von Diltiazem | |
| EP0024023B2 (de) | Antimykotische Mittel mit höherer Freisetzung der Wirkstoffe | |
| DE69023939T2 (de) | Förderung der Osteogenese durch Verwendung von Vitamin D-Derivaten. | |
| CH621333A5 (enrdf_load_html_response) | ||
| EP0043548B1 (de) | Salz aus Furosemid oder Piretanid als Säurekomponente und Penbutolol als Basenkomponente sowie Arzneimittel, das beide Komponenten enthält | |
| DE19810999A1 (de) | Verwendung von Sphingosin, Sphingosin-1-Phosphat, Sphingosin-1-Phosphat-Derivaten und/oder deren Gemischen zur Behandlung von entzündlichen Hautkrankheiten | |
| DE2515594B2 (de) | Verfahren zur Herstellung eines stabilen, topisch aktiven Geles | |
| AT392002B (de) | Verwendung von peroxydiphosphaten zur herstellung von pharmazeutischen tabletten bzw. pharmazeutischen waesserigen loesungen | |
| DE3628190A1 (de) | Pharmazeutische zusammensetzung zur behandlung von parathyreoid-hormon induzierter knochenresorption | |
| DE3424997C2 (enrdf_load_html_response) | ||
| DE3212909C2 (enrdf_load_html_response) | ||
| EP0013252B1 (de) | Mittel zur Senkung der Herzfrequenz | |
| DE3627759A1 (de) | Pharmazeutische zusammensetzung zum inaktivieren bakterieller endotoxine | |
| DE1908574A1 (de) | Neue antiseborrhoeische Verbindungen,Verfahren zu ihrer Herstellung,kosmetische Mittel,Shampoos und oral verabreichbare Produkte mit einem Gehalt an diesen neuen Verbindungen | |
| DE60018438T2 (de) | Pharmazeutische und/oder kosmetische zusammensetzungen | |
| DE1068701B (de) | Verfahren zur Herstellung von antibiotisch wirksamem Tetracyclinnatriumhexametaphosphat | |
| DE2916880C2 (de) | Arzneimittel mit sedativer und schlafinduzierender Wirkung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8128 | New person/name/address of the agent |
Representative=s name: STOLBERG-WERNIGERODE, GRAF ZU, U., DIPL.-CHEM. DR. |
|
| 8110 | Request for examination paragraph 44 | ||
| 8136 | Disposal/non-payment of the fee for publication/grant |